Skip to main content
Swing Capital

Balaxi Pharmaceuticals Ltd

NSE: BALAXIPharma

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]

₹24.6
52W: ₹15.2 — ₹63.9
PE 35.7 · Book ₹23.8 · +3% vs book
Market Cap₹136 Cr
Stock P/E35.7Price to Earnings
ROCE5.06%Return on Capital
ROE2.89%Return on Equity
Div. Yield0%Face Value ₹2

Strengths

  • +Stock is trading at 1.03 times its book value
  • +Company is expected to give good quarter

Weaknesses

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 5.97% over past five years.
  • −Company has a low return on equity of 7.67% over last 3 years.
  • −Earnings include an other income of Rs.6.61 Cr.
  • −Company has high debtors of 538 days.
  • −Promoter holding has decreased over last 3 years: -6.70%

Shareholding Pattern

Promoters65.99%
FIIs0%
DIIs2.56%
Public31.45%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters65.99%65.99%65.99%65.99%65.99%65.99%65.99%65.99%
FIIs16.88%16.48%▼0.416.48%16.02%▼0.58.87%▼7.23.5%▼5.41.74%▼1.80%▼1.7
DIIs0.02%0.02%0.02%0.02%0.02%0.02%0.02%2.56%▲2.5
Public17.11%17.5%▲0.417.5%17.96%▲0.525.12%▲7.230.49%▲5.432.24%▲1.831.45%▼0.8

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales16.5512.715.919.0321.1611.169.6516.7119.3124.59
Expenses15.6412.4215.717.5319.6811.0610.3116.1718.5323.21
Operating Profit0.910.280.21.51.480.1-0.660.540.781.38
OPM %5.5%2.2%1.26%7.88%6.99%0.9%-6.84%3.23%4.04%5.61%
Net Profit1.180.49-0.581.381.661.74-1.180.193.261.53
EPS ₹0.230.1-0.110.250.30.32-0.210.030.590.28

AI Insights

Revenue Trend

TTM revenue at ₹70.26Cr, up 15.2% YoY. OPM at 2.9%.

Debt Position

Borrowings at ₹35.16Cr. Debt-to-equity ratio: 0.29x. Healthy balance sheet.

Capex Cycle

CWIP at ₹34.28Cr (529% of fixed assets). Significant capex underway — growth runway building.

Institutional Flow

DIIs: 2.56% (+2.53pp change). FIIs: 0% (-18.57pp change). Promoters hold 65.99%.

Margin & Efficiency

ROCE declining from 17.11% (Mar 2014) to 5.06% (Mar 2025). Working capital days: 282.17.

Valuation

PE 35.7x with 5.06% ROCE. Price is 3% above book value of ₹23.8. Dividend yield: 0%.

Recent Announcements